Testing effectiveness (Phase 2)Study completedNCT06073119What this trial is testingEvaluate Efficacy and Safety of SAR441566 in Adults With Plaque PsoriasisWho this might be right forPsoriasis Sanofi 221
Large-scale testing (Phase 3)Study completedNCT03047395What this trial is testingAssess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )Who this might be right forPsoriasis AbbVie 2,170
Large-scale testing (Phase 3)Study completedNCT04435600What this trial is testingSubcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease SymptomsWho this might be right forPsoriasis AbbVie 139
Large-scale testing (Phase 3)Study completedNCT02684357What this trial is testingBI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque PsoriasisWho this might be right forPsoriasis AbbVie 577
Large-scale testing (Phase 3)Study completedNCT01177800What this trial is testingEvaluate Safety and Efficacy of Infliximab in Chinese Participants With Moderate to Severe Plaque-type PsoriasisWho this might be right forPsoriasis Xian-Janssen Pharmaceutical Ltd. 129
Post-approval studies (Phase 4)Study completedNCT05969223What this trial is testingStudy to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp PsoriasisWho this might be right forGenital PsoriasisScalp Psoriasis AbbVie 214
Testing effectiveness (Phase 2)Study completedNCT00941031What this trial is testingAIN457 Regimen Finding Study in Patients With Moderate to Severe PsoriasisWho this might be right forChronic Plaque-type Psoriasis Novartis Pharmaceuticals 404
Testing effectiveness (Phase 2)Study completedNCT01483924What this trial is testingStudy to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque PsoriasisWho this might be right forPlaque Psoriasis ApoPharma 60
Large-scale testing (Phase 3)Study completedNCT00109317What this trial is testingEvaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic TherapyWho this might be right forPsoriasis Genentech, Inc. 686
Not applicableStudy completedNCT04894890What this trial is testingA Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in ChinaWho this might be right forPsoriasis Novartis Pharmaceuticals 1,002
Large-scale testing (Phase 3)Active Not RecruitingNCT06425549What this trial is testingEvaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque PsoriasisWho this might be right forModerate to Severe Plaque Psoriasis UCB Biopharma SRL 176
Not applicableActive Not RecruitingNCT06512337What this trial is testingA Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in ChinaWho this might be right forPlaque Psoriasis Bristol-Myers Squibb 153
Post-approval studies (Phase 4)Study completedNCT03403036What this trial is testingBrodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A TherapiesWho this might be right forPsoriasis Icahn School of Medicine at Mount Sinai 39
Testing effectiveness (Phase 2)WithdrawnNCT03298581What this trial is testingMultiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Plaque PsoriasisWho this might be right forPlaque Psoriasis Sun Pharmaceutical Industries Limited
Large-scale testing (Phase 3)Looking for participantsNCT07116967What this trial is testingLong-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)Who this might be right forPlaque Psoriasis Bristol-Myers Squibb 3,040
Large-scale testing (Phase 3)Study completedNCT02394561What this trial is testingA 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)Who this might be right forPlaque Type Psorisis Novartis Pharmaceuticals 434
Large-scale testing (Phase 3)Ended earlyNCT00358670What this trial is testingLong-Term Effects of Infliximab in the Treatment of Moderate to Severe Psoriasis [Extension of Study P04271, NCT00251641] (P04563)Who this might be right forPsoriasis Merck Sharp & Dohme LLC 441
Testing effectiveness (Phase 2)Study completedNCT00245765What this trial is testingEfficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/PhotochemotherapyWho this might be right forChronic Plaque Psoriasis UCB Pharma 176
Large-scale testing (Phase 3)Study completedNCT00647400What this trial is testingAdalimumab in Adult Japanese Subjects With PsoriasisWho this might be right forPsoriasis Abbott 147
Testing effectiveness (Phase 2)Study completedNCT03837743What this trial is testingSafety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque PsoriasisWho this might be right forPlaque Psoriasis Durect 25